In the single xenograft (AML-XG1) in which splenic AML engraftment was observed, the proportion of human CD45+/CD33+ cells in the spleen were significantly lower in all treatment groups when compared with controls (Figure 4C). Here, CD33 is linked to acute myeloid leukemia.